C9467 — Injection, rituximab and hyaluronidase, 10 mg
C9467 is a HCPCS Level II code for injection, rituximab and hyaluronidase, 10 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on December 31, 2018 and is not valid on new claims.
This code has been terminated
CMS terminated C9467 on December 31, 2018. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9467
- Long descriptor
- Injection, rituximab and hyaluronidase, 10 mg
- Short descriptor
- Inj rituximab hyaluronidase
- Added
- April 1, 2018
- Terminated
- December 31, 2018
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9467
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9467 is not quite right, the correct code is very often within a few positions of it.
- C9459Flutemetamol f18, diagnostic, per study dose, up to 5 millicuriesterminated
- C9460Injection, cangrelor, 1 mg
- C9461Choline c 11, diagnostic, per study doseterminated
- C9462Injection, delafloxacin, 1 mg
- C9463Injection, aprepitant, 1 mgterminated
- C9464Injection, rolapitant, 0.5 mgterminated
- C9465Hyaluronan or derivative, durolane, for intra-articular injection, per doseterminated
- C9466Injection, benralizumab, 1 mgterminated
- C9468Injection, factor ix (antihemophilic factor, recombinant), glycopegylated, rebinyn, 1 i.u.terminated
- C9469Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mgterminated
- C9470Injection, aripiprazole lauroxil, 1 mgterminated
- C9471Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mgterminated
- C9472Injection, talimogene laherparepvec, 1 million plaque forming units (pfu)terminated
- C9473Injection, mepolizumab, 1 mgterminated
- C9474Injection, irinotecan liposome, 1 mgterminated
- C9475Injection, necitumumab, 1 mgterminated
Questions about C9467
What is HCPCS code C9467?
C9467 is a HCPCS Level II code for injection, rituximab and hyaluronidase, 10 mg. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9467?
The CMS HCPCS file marks C9467 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9467 still valid?
No. C9467 was terminated on December 31, 2018 and should not be used on new claims.